The high affinity of CXCR2 to chemokines has been shown to be associated with the prognosis of patients with many cancers, including glioblastoma, colon cancer, lung cancer, hepatocellular carcinoma, and pancreatic cancer [19–23]. Here, CXCR2 is linked to lung carcinoma.